"Azfdin (FNC)" was approved for listing: small dosage, good effect, and fast virus decrease

Elephant News · Henan Radio and Television Station Lu Jiamin Xinxiang Reporter Station Townson Chen Peizheng Xinxiangtai Shao Fangwei Shao Fangwei Ji Hongfei

The clinical trial results show:

Azf's fixed tablet can significantly improve clinical symptoms, which can significantly shorten the moderate new new coronary virus infection with pneumonia patients' symptoms; Azf will have the effect of inhibiting the new coronary virus, the virus clearance time is about 5 days; in terms of safety, Ah, Ah, Ah, Ah, Ah, Ah, Ah, Ah, Ah, Ah, Ah; The overall tolerance of Zif's fixed film is good, and the incidence of adverse events has no statistical differences with the placebo group, and the risk of subjects does not increase. Azfdin, referred to as FNC for short, is a kind of anti -new coronary pneumonia small molecule oral medication that can inhibit virus replication. It is developed by Henan scientists, Henan Laboratory, and Henan enterprises. Since April 2020, Azfding has successively launched a phase III clinical trial in my country and abroad. On the afternoon of July 25, Azfding (FNC) was officially approved to be listed.

Small dosage effect Has a good virus drops fast

According to Professor Chang Junbiao, the inventor of Azfud (FNC): "From the current clinical effects, combined with our early scientific research clinical trials, this drug has very good effect on some critical patients. Pneumonia virus variation (Alpha, Beta, Delta, Omikon, etc.), Azf has the characteristics of very small dosage, good therapeutic effect, and very fast virus decrease.

The reporter learned that more than 800 patients with phase III clinical trials covered the mildness, neutral and severe illnesses of new crown pneumonia cases, and using virus load and clinical benefits as evaluation indicators, which is very conducive to the efficacy of the drug's curative effect. Make comprehensive and comprehensive evaluation.

Drug activity is good toxic and side effects, small specimens and cure

In addition to the characteristics of "small dosage, good therapeutic effect, and fast virus falling speed", Professor Chang Junbiao also told reporters that "Azf's active target is special, drug activity, good treatment effect, small toxic and side effects, is that it is, is that it is small. A drug with both specimens. "

Jiang Jiandong, an academician of the Chinese Academy of Engineering and the dean of the Beijing Academy of Pharmaceutical Research, Chinese Academy of Medical Sciences.

Flowing spectrum inhibitory RNA virus copy for about 5 days to clear the new coronal virus

According to Professor Chang Junbiao, Azfdin was developed for antiviral drugs at first. It was the world's first double -target anti -AIDS innovative drug. Researchers have found that Azf will have a broad -spectrum to inhibit RNA virus replication, while the new crown virus belongs to the virus of RNA as a genetic material. Therefore, the drug has a very good activity of the new crown virus. about.

Since the outbreak of the new coronary pneumonia, Professor Chang Junbiao and Dr. Du Jinfa, Chairman of Henan Real Biotechnology Co., Ltd., Chairman Chao Chaoyang, Executive Vice President Liu Yong, Academician Jiang Jiandong, Academician Wang Chen, and Researcher Peng Xiaoyong, Beijing Earthquake Professor Zhang Fujie of the Hospital, the scientific research team led by Professor Yu Zujiang, Dr. Ren Zhigang, etc., the First Affiliated Hospital of Zhengzhou University. Effective studies, clinical trials and other series of work, and actively promote the listing of Azfding (FNC) anti -new crown drugs.

Professor Chang Junbiao said: "For the new coronary pneumonia virus, Azfdin (FNC) is a very good drug. I believe that in the future, this drug will play a great role at home and abroad. Global showing our Chinese nation's scientific and technological power. "

According to the reporter, Azf is the first 1.1 type 1.1 anti -new crown pneumonia small molecules oral drugs with a global patent.

- END -